search
Back to results

Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection

Primary Purpose

Surgical Site Infection

Status
Unknown status
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
Stimulan Rapid Cure
Vancomycin
Tobramycin
Standard of Care
Sponsored by
McMaster University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Surgical Site Infection focused on measuring Vascular Surgery, Surgical Site Infection, Prophylactic Antibiotics, Implantable Beads

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Men and women aged > 18
  • Undergoing a revascularization procedure involving the femoral artery and requiring either unilateral or bilateral groin incision
  • BMI > 30
  • Presence of one of the following: current smoker, diabetes requiring pharmacologic intervention, previous re-vascularization procedure

Exclusion Criteria:

  • Any patient with a current infection or requiring ongoing use of antibiotics
  • Any patient who otherwise has an indication requiring the use of antibiotic impregnated material
  • Known allergy or sensitivity to tobramycin or vancomycin
  • Grade 4 or 5 chronic kidney disease
  • Moderate or severe hypercalcemia
  • Any woman currently pregnant or planning on becoming pregnant during the course of the study
  • Any patient involved in another study that, in the investigators opinion, is believed will interfere with the study

Sites / Locations

  • Hamilton General HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Experimental

Arm Label

Standard of Care

Antibiotic Impregnated Beads

Arm Description

Patients will receive the standard of care for vascular procedures as it is provided at Hamilton General Hospital

Patients will have their wound packed with calcium sulfate beads prior to closing. The beads will be infused with the antibiotics vancomycin and tobramycin.

Outcomes

Primary Outcome Measures

Surgical Site Infection
The primary outcome will be combined, superficial, deep or organ/space infection as defined by the CDC. The CDC definition for surgical site infection is one of the most widely used and is both the NSQUIP and NHSN definition.

Secondary Outcome Measures

Wound Complication Rate
Wound complications will be defined as: wound dehiscence, skin edge necrosis, hematoma, seroma, increased wound exudate, graft exposure. These will be measured with a standardized form, by the blinded nurse assessor, at each follow-up appointment. They will additionally be assessed by the author reviewing patient records at thirty days. If imaging is required for diagnosis of hematoma or seroma, the result will be collected from the imaging records, and treated as consistent with the conclusions of the formal imaging report.
Surgical Graft Infection Rate
Graft infection is defined as; diagnosis by surgeon or surgical designate requiring re-operation or prolonged course of antibiotic therapy. An author blinded to patient treatment will review the records of the patient including patient charts, antibiotic prescriptions, home care and ID referrals and record the information in a standardized form for this endpoint.
Bacterial Resistance
In the event of infection requiring laboratory samples, screening for resistant bacteria will be performed. Bacterial cultures will be performed in order to determine the presence of tobramycin or vancomycin resistant strains.

Full Information

First Posted
October 3, 2017
Last Updated
July 17, 2018
Sponsor
McMaster University
search

1. Study Identification

Unique Protocol Identification Number
NCT03308253
Brief Title
Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection
Official Title
Pilot Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection in Vascular Surgery Patients
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Unknown status
Study Start Date
July 16, 2018 (Actual)
Primary Completion Date
June 2019 (Anticipated)
Study Completion Date
July 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
McMaster University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The CDC quotes a rate of wound infection of 2-5% for inpatient surgery. Patients undergoing a vascular operation, however, are generally at an increased risk of wound infection with rates often close to 5-10%. Groin incisions are an additional risk factor for surgical site infections, with rates of wound infection being quoted from 10-15%, and even as high as 30% in high risk patients. The use of implantable calcium sulfate beads mixed with antibiotics may help to lower the rate of infection in these high risk patients.
Detailed Description
The initial pilot will consist of 30 patients per arm and will provide estimates of effect size, event rates, and recruitment rates. It will mirror the final study in terms of methodology. This will occur at the Hamilton General Hospital (Hamilton, ON. Canada) Patients will be randomized to either the exposure group or control group by the study coordinator. Patients will be block randomized among surgeons (6), so that each surgeon has an equal number of patients in the control and exposure arms. Randomization will occur once an operative date has been booked for a patient. The arm they are assigned to will be how the patient is treated, regardless of if they are cancelled and re-booked. Should patients be done as an emergency procedure, prior to their index procedure (when the beads would be implanted), they will be excluded from the study. As no intervention has occurred at this point, there will be no informative loss to follow-up or censoring and therefore this will not impact validity of the design. We are unable to provide beads for emergency procedures, as the research pharmacy is not open. The research coordinator will inform the research pharmacy to produce calcium sulfate beads impregnated with Vancomycin (1g) and Tobramycin (240mg) for the exposure arm. The control arm will receive standard care. The only difference between standard care and the treatment arm is the use of the antibiotic calcium sulfate beads. Beads will be delivered in a sterile manner to the OR. For each patient half of a standard 10cc kit will be delivered (5cc of Stimulan Calcium Sulfate). As the beads are being applied only to a groin incision(s) this will provide an adequate volume of beads. It will also prevent insertion of excess beads. Surgeons will insert the beads loosely within the soft tissue of groin incisions, so as not to distort the normal anatomy. This technique will be discussed with all surgeons prior to pilot initiation as a group. This will aim to standardize the method among involved surgeons. At the end of the study we will complete a focus group with surgeons to discuss their experience using the beads to better inform the protocol for the final RCT. Patients are randomized as a unit and therefore, if there are bilateral groin incisions, both will be treated as per their randomization. Patients will be blinded to which treatment they receive. The beads are believed to be non-detectable to the patient. Only by means of wound dehiscence would a patient be expected to determine their treatment group. For practical reasons the surgeon cannot be blinded to treatment. Nurse assessors and study authors conducting review of patient records will be blinded to patient treatment. Patients will be recruited from all patients consented for an included procedure at HGH. A study coordinator or a resident will obtain consent. The patient's primary physician will not be involved in the consent process.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Surgical Site Infection
Keywords
Vascular Surgery, Surgical Site Infection, Prophylactic Antibiotics, Implantable Beads

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard of Care
Arm Type
Other
Arm Description
Patients will receive the standard of care for vascular procedures as it is provided at Hamilton General Hospital
Arm Title
Antibiotic Impregnated Beads
Arm Type
Experimental
Arm Description
Patients will have their wound packed with calcium sulfate beads prior to closing. The beads will be infused with the antibiotics vancomycin and tobramycin.
Intervention Type
Device
Intervention Name(s)
Stimulan Rapid Cure
Intervention Description
Calcium sulfate dissolvable beads
Intervention Type
Drug
Intervention Name(s)
Vancomycin
Intervention Description
0.5 g Vancomycin per patient
Intervention Type
Drug
Intervention Name(s)
Tobramycin
Intervention Description
120 mg tobramycin per patient
Intervention Type
Other
Intervention Name(s)
Standard of Care
Intervention Description
Standard of care provided at Hamilton General Hospital consisting of dressings for the wound.
Primary Outcome Measure Information:
Title
Surgical Site Infection
Description
The primary outcome will be combined, superficial, deep or organ/space infection as defined by the CDC. The CDC definition for surgical site infection is one of the most widely used and is both the NSQUIP and NHSN definition.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Wound Complication Rate
Description
Wound complications will be defined as: wound dehiscence, skin edge necrosis, hematoma, seroma, increased wound exudate, graft exposure. These will be measured with a standardized form, by the blinded nurse assessor, at each follow-up appointment. They will additionally be assessed by the author reviewing patient records at thirty days. If imaging is required for diagnosis of hematoma or seroma, the result will be collected from the imaging records, and treated as consistent with the conclusions of the formal imaging report.
Time Frame
30 day
Title
Surgical Graft Infection Rate
Description
Graft infection is defined as; diagnosis by surgeon or surgical designate requiring re-operation or prolonged course of antibiotic therapy. An author blinded to patient treatment will review the records of the patient including patient charts, antibiotic prescriptions, home care and ID referrals and record the information in a standardized form for this endpoint.
Time Frame
90 day
Title
Bacterial Resistance
Description
In the event of infection requiring laboratory samples, screening for resistant bacteria will be performed. Bacterial cultures will be performed in order to determine the presence of tobramycin or vancomycin resistant strains.
Time Frame
30 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men and women aged > 18 Undergoing a revascularization procedure involving the femoral artery and requiring either unilateral or bilateral groin incision BMI > 30 Presence of one of the following: current smoker, diabetes requiring pharmacologic intervention, previous re-vascularization procedure Exclusion Criteria: Any patient with a current infection or requiring ongoing use of antibiotics Any patient who otherwise has an indication requiring the use of antibiotic impregnated material Known allergy or sensitivity to tobramycin or vancomycin Grade 4 or 5 chronic kidney disease Moderate or severe hypercalcemia Any woman currently pregnant or planning on becoming pregnant during the course of the study Any patient involved in another study that, in the investigators opinion, is believed will interfere with the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Steven Phillips, MSc
Phone
905-521-2100
Ext
44167
Email
phills3@mcmaster.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael C Stacey, DS
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hamilton General Hospital
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8L 2X2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steven Phillips, MSc
Phone
905-521-2100
Ext
44167
Email
phills3@mcmaster.ca
First Name & Middle Initial & Last Name & Degree
Michael C Stacey
First Name & Middle Initial & Last Name & Degree
Brandon McGuinness

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Individual patient data will not be shared for this pilot study.

Learn more about this trial

Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection

We'll reach out to this number within 24 hrs